• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文会议>Health Science International Conference >Selected Benefits of Pentoxifylline in Acute Ischemic Stroke Management: Consideration of Risk Factors
【24h】

Selected Benefits of Pentoxifylline in Acute Ischemic Stroke Management: Consideration of Risk Factors

机译：急性缺血性卒中管理中的戊氧化碱的选定益处：考虑风险因素

获取原文
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Background: The role of pentoxifylline in acute ischemic stroke lacks objective markers of its efficacy. In this study, we used blood viscosity as a specific marker to evaluate the efficacy of pentoxifylline. Objectives: This quasi-experimental study aimed to analyze pentoxifylline as an antihemorrheologic agent in acute ischemic stroke patients with certain risk factors, including age, smoking, hypertension, dyslipidemia, diabetes mellitus, and ischemic heart disease. Method: There were 22 acute ischemic stroke patients with blood hyper viscosity within 72 hours of onset who received pentoxifylline 1.200 mg/day for five days and continued with oral dose 400 mg twice daily for the next twenty-three days. All subjects received the standard treatment for acute ischemic stroke. The risk factors of stroke were recorded including smoking, hypertension, dyslipidemia, diabetes mellitus, and ischemic heart disease. Results: The median of baseline blood viscosity was 6.46 poise (5.20-9.73). The blood viscosity at the seventh and thirtieth day tend to decrease. The mean decrement blood viscosity level was statistically significant in smoking (p=0.009) and dyslipidemia (p=0.006) subjects. Clinical outcomes were assessed using the National Institutes of Health Stroke Scale (NIHSS), modified Rankin scale (mRS), and Barthel Index (BI). All subjects had good functional outcome and statistically significant for those who had diabetes mellitus and heart disease. Conclusion: Pentoxifylline is beneficial for acute ischemic stroke patients with risk factors of smoking, dyslipidemia, diabetes mellitus, and heart disease.
机译：背景：五氧化酶在急性缺血中风中的作用缺乏其疗效的客观标志。在这项研究中，我们使用血液粘度作为特定标记物，以评估戊氧化碱基的功效。目的：这种准实验研究旨在分析急性缺血性脑卒中患者的抗血血病患者的抗血血病患者，包括某些危险因素，包括年龄，吸烟，高血压，血液化血症，糖尿病和缺血性心脏病。方法：在疾病的72小时内患有22例急性缺血性脑卒中患者，患有戊氧化碱1.200毫克/天5天，并在每天两次持续400毫克，每天两次23天。所有受试者得到急性缺血性卒中的标准治疗。记录中风的危险因素包括吸烟，高血压，血脂血症，糖尿病和缺血性心脏病。结果：基线血液粘度的中位数为6.46泊（5.20-9.73）。第七和第三十天的血液粘度往往会降低。在吸烟（P = 0.009）和血脂血症（P = 0.006）受试者中，平均衰减血液粘度水平在统计学上显着。使用国家卫生冲程量表（NIHSS），改进的Rankin规模（MRS）和Barthel指数（BI）评估临床结果。所有受试者均具有良好的功能结果，对那些患有糖尿病和心脏病的人具有统计学意义。结论：Pentoximimlline对急性缺血性脑卒中患者有益的吸烟，血脂血症，糖尿病和心脏病。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号